This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD152 (CTLA-4) Monoclonal Antibody (UC10-4B9), PE-eFluor 610, eBioscience
catalog :
61-1522-82
quantity :
100 ug
price :
US 407.00
clonality :
monoclonal
host :
hamsters
conjugate :
PE-eFluor 610
clone name :
UC10-4B9

The same clone is also sold as:
reactivity :
mouse
application :
flow cytometry
citations: 16
Reference
Yu L, Zhou B, Zhu Y, Li L, Zhong Y, Zhu L, et al. HSF1 promotes CD69+ Treg differentiation to inhibit colitis progression. Theranostics. 2023;13:1892-1905 pubmed publisher
Masle Farquhar E, Jeelall Y, White J, Bier J, Deenick E, Brink R, et al. CARD11 gain-of-function mutation drives cell-autonomous accumulation of PD-1+ ICOShigh activated T cells, T-follicular, T-regulatory and T-follicular regulatory cells. Front Immunol. 2023;14:1095257 pubmed publisher
Ma B, Kamle S, Akosman B, Khan H, Lee C, Lee C, et al. CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. Front Immunol. 2022;13:1056397 pubmed publisher
Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, et al. CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver. Aging Dis. 2022;13:1919-1938 pubmed publisher
Kalim K, Yang J, Modur V, Nguyen P, Li Y, Zheng Y, et al. Graded RhoA GTPase Expression in Treg Cells Distinguishes Tumor Immunity From Autoimmunity. Front Immunol. 2021;12:726393 pubmed publisher
Lou Y, Wang J, Peng P, Wang S, Liu P, Xu L. Downregulated TNF-α Levels after Cryo-Thermal Therapy Drive Tregs Fragility to Promote Long-Term Antitumor Immunity. Int J Mol Sci. 2021;22: pubmed publisher
Skordos I, Demeyer A, Beyaert R. Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry. STAR Protoc. 2021;2:100351 pubmed publisher
Srivastava S, Furlan S, Jaeger Ruckstuhl C, Sarvothama M, Berger C, Smythe K, et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 2021;39:193-208.e10 pubmed publisher
Ferrere G, Tidjani Alou M, Liu P, Goubet A, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6: pubmed publisher
Liu W, Dai E, Liu Z, Ma C, Guo Z, Bartlett D. In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Mol Ther Oncolytics. 2020;17:350-360 pubmed publisher
Demeyer A, Skordos I, Driege Y, Kreike M, Hochepied T, Baens M, et al. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner. Front Immunol. 2019;10:1898 pubmed publisher
Lu Y, Kim N, Jiang Y, Zhang H, Zheng D, Zhu F, et al. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol. 2018;175:1085-1099 pubmed publisher
Peer S, Baier G, Gruber T. Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget. 2017;8:41841-41853 pubmed publisher
Zamarin D, Holmgaard R, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340 pubmed publisher
Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
Tähtinen S, Kaikkonen S, Merisalo Soikkeli M, Grönberg Vähä Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS ONE. 2015;10:e0131242 pubmed publisher
product information
Product Type :
Antibody
Product Name :
CD152 (CTLA-4) Monoclonal Antibody (UC10-4B9), PE-eFluor 610, eBioscience
Catalog # :
61-1522-82
Quantity :
100 ug
Price :
US 407.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Armenian Hamster
Reactivity :
Mouse
Applications :
Flow Cytometry: 0.5 ug/test
Species :
Mouse
Clone :
UC10-4B9
Isotype :
IgG
Storage :
4 C, store in dark, DO NOT FREEZE!
Description :
CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T cells. It binds the same ligands as CD28 (CD80 and CD86 on B cells and dendritic cells), but with higher affinity than CD28. However, in contrast to CD28 which enhances cell function when bound at the same time as the T cell receptor, CTLA4 inhbits the T cell and prevents it from functioning. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.5 ug/test
Aliases :
ALPS5; CD; CD152; CD152 antigen; CD152 isoform; CD152 protein; CD152 protein precursor; celiac disease 3; CELIAC3; Ctla4; CTLA-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte associated protein 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; EGK_04712; GRD4; GSE; ICOS; IDDM12; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; Ly-56; sCTLA4; soluble form; transmembrane form
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA